港股異動 | 中國生物科技服務(8037.HK)大漲19% 股價創近2年半新高
格隆匯2月5日丨中國生物科技服務(8037.HK)高開高走,盤中高見2.1港元創2018年8月30日以來近2年半新高,現報2港元,大漲19.05%,最新總市值19億港元。據悉,中國生物科技服務旗下子公司上海隆耀生物科技有限公司的首席科學家楊選明教授關於CD20-CART-OX40的文章在美國東部時間1月27日正式發表於Science Translational Medicine。此外,根據聯交所最新權益披露資料,中國生物科技服務於1月22日獲股東高振順在場內斥資約1009.5萬港元增持754.5萬股,增持後,其持股比例由4.96%上升至5.74%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.